Single-spanning transmembrane domains in cell growth and cell-cell interactions: More than meets the eye?

Cell Adhesion and Migration

Volumn 4, Issue 2, 2010, Pages 313-324

  Hubert, Pierre ^a   Sawma, Paul ^a   Duneau, Jean Pierre ^a   Khao, Jonathan ^a   Hénin, Jérôme ^a   Bagnard, Dominique ^b   Sturgis, James ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Bitopic membrane proteins; Helix helix interactions; Receptors; Transmembrane domains; Transmembrane signaling

Indexed keywords

BITOPIC PROTEIN; GLYCOPHORIN A; MEMBRANE PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO ACID SEQUENCE; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; DIMERIZATION; HUMAN; LIPID BILAYER; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

ANIMALS; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 77953584951     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.4.2.12430     Document Type: Review

References (178)

1. Stevens TJ, Arkin IT. Do more complex organisms have a greater proportion of membrane proteins in their genomes? Proteins 2000; 39:417-20.
2. Fagerberg L, Jonasson K, von Heijne G, Uhlen M, Berglund L. Prediction of the human membrane proteome. Proteomics 2010; 10:1-9.
3. Arinaminpathy Y, Khurana E, Engelman DM, Gerstein MB. Computational analysis of membrane proteins: the largest class of drug targets. Drug Discov Today 2009; 14:1130-5.
4. Reshetnyak YK, Segala M, Andreev OA, Engelman DM. A monomeric membrane peptide that lives in three worlds: in solution, attached to and inserted across lipid bilayers. Biophys J 2007; 93:2363-72.
5. Glukhov E, Burrows LL, Deber CM. Membrane interactions of designed cationic antimicrobial peptides: The two thresholds. Biopolymers 2008; 89:360-71.
6. Mahalka AK, Kinnunen PK. Binding of amphipathic alpha-helical antimicrobial peptides to lipid membranes: lessons from temporins B and L. Biochim Biophys Acta 2009; 1788:1600-9.
7. Bechinger B. A dynamic view of peptides and proteins in membranes. Cell Mol Life Sci 2008; 65:3028-39.
8. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 1972; 175:720-31.
9. Engelman DM. Membranes are more mosaic than fluid. Nature 2005; 438:578-80.
10. Grasberger B, Minton AP, DeLisi C, Metzger H. Interaction between proteins localized in membranes. Proc Natl Acad Sci USA 1986; 83:6258-62.
11. Matthews EE, Zoonens M, Engelman DM. Dynamic helix interactions in transmembrane signaling. Cell 2006; 127:447-50.
12. Langosch D, Arkin IT. Interaction and conformational dynamics of membrane-spanning protein helices. Protein Sci 2009; 18:1343-58.
13. Lindner R, Naim HY. Domains in biological membranes. Exp Cell Res 2009; 315:2871-8.
14. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 2010; 327:46-50.
15. Popot JL, Engelman DM. Membrane protein folding and oligomerization: the two-stage model. Biochemistry 1990; 29:4031-7.
16. Engelman DM, Chen Y, Chin CN, Curran AR, Dixon AM, Dupuy AD, et al. Membrane protein folding: beyond the two stage model. FEBS Lett 2003; 555:122-5.
17. Cebecauer M, Spitaler M, Serge A, Magee AI. Signalling complexes and clusters: functional advantages and methodological hurdles. J Cell Sci 2010; 123:309-20.
18. Nelson N, Yocum CF. Structure and function of photosystems I and II. Annu Rev Plant Biol 2006; 57:521-65.
19. Devenish RJ, Prescott M, Rodgers AJ. The structure and function of mitochondrial F1F0-ATP synthases. Int Rev Cell Mol Biol 2008; 267:1-58.
20. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5:453-63.
21. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides and coreceptors. Annu Rev Immunol 2006; 24:419-66.
22. Sigalov AB. SCHOOL model and new targeting strategies. Adv Exp Med Biol 2008; 640:268-311.
23. Vamosi G, Bodnar A, Damjanovich S, Nagy P, Varga Z, Damjanovich L. The role of supramolecular protein complexes and membrane potential in transmembrane signaling processes of lymphocytes. Immunol Lett 2006; 104:53-8. (Pubitemid 43330709)
24. Milligan G. G protein-coupled receptor heterodimerization: contribution to pharmacology and function. Br J Pharmacol 2009; 158:5-14.
25. Rozenfeld R, Devi LA. Receptor heteromerization and drug discovery. Trends Pharmacol Sci 2010; 31:124-30.
26. Bordag N, Keller S. Alpha-helical transmembrane peptides: a "divide and conquer" approach to membrane proteins. Chem Phys Lipids 2010; 163:1-26.
27. White SH. Biophysical dissection of membrane proteins. Nature 2009; 459:344-6.
28. Rath A, Tulumello DV, Deber CM. Peptide models of membrane protein folding. Biochemistry 2009; 48:3036-45.
29. Harrington SE, Ben-Tal N. Structural determinants of transmembrane helical proteins. Structure 2009; 17:1092-103.
30. Arce J, Sturgis JN, Duneau JP. Dissecting membrane protein architecture: An annotation of structural complexity. Biopolymers 2009; 91:815-29.
31. Moore DT, Berger BW, DeGrado WF. Protein-Protein Interactions in the Membrane: Sequence, Structural and Biological Motifs. Structure 2008; 16:991-1001.
32. Marsh D. Protein modulation of lipids and viceversa, in membranes. Biochim Biophys Acta 2008; 1778:1545-75.
33. Mackenzie KR, Fleming KG. Association energetics of membrane spanning alpha-helices. Curr Opin Struct Biol 2008; 18:412-19.
34. Zviling M, Kochva U, Arkin IT. How important are transmembrane helices of bitopic membrane proteins? Biochim Biophys Acta 2007; 1768:387-92.
35. von Heijne G. The membrane protein universe: what's out there and why bother? J Intern Med 2007; 261:543-57.
36. Schneider D, Finger C, Prodohl A, Volkmer T. From interactions of single transmembrane helices to folding of alpha-helical membrane proteins: analyzing transmembrane helix-helix interactions in bacteria. Curr Protein Pept Sci 2007; 8:45-61.
37. Rath A, Johnson RM, Deber CM. Peptides as transmembrane segments: decrypting the determinants for helix-helix interactions in membrane proteins. Biopolymers 2007; 88:217-32.
38. Walters RF, DeGrado WF. Helix-packing motifs in membrane proteins. Proc Natl Acad Sci USA 2006; 103:13658-63.
39. Sachs JN, Engelman DM. Introduction to the membrane protein reviews: the interplay of structure, dynamics and environment in membrane protein function. Annu Rev Biochem 2006; 75:707-12.
40. Mackenzie KR. Folding and stability of alpha-helical integral membrane proteins. Chem Rev 2006; 106:1931-77.
41. White SH. Membrane protein insertion: the biology-physics nexus. J Gen Physiol 2007; 129:363-9.
42. Jones DT, Taylor WR, Thornton JM. A mutation data matrix for transmembrane proteins. FEBS Lett 1994; 339:269-75.
43. Herrmann JR, Panitz JC, Unterreitmeier S, Fuchs A, Frishman D, Langosch D. Complex patterns of histidine, hydroxylated amino acids and the GxxxG motif mediate high-affinity transmembrane domain interactions. J Mol Biol 2009; 385:912-23.
44. Senes A, Engel DE, DeGrado WF. Folding of helical membrane proteins: the role of polar, GxxxG-like and proline motifs. Curr Opin Struct Biol 2004; 14:465-79.
45. Dawson JP, Melnyk RA, Deber CM, Engelman DM. Sequence context strongly modulates association of polar residues in transmembrane helices. J Mol Biol 2003; 331:255-62.
46. Herrmann JR, Fuchs A, Panitz JC, Eckert T, Unterreitmeier S, Frishman D, et al. Ionic Interactions Promote Transmembrane Helix-Helix Association Depending on Sequence Context. J Mol Biol 2010; 396:452-61.
47. Melnyk RA, Kim S, Curran AR, Engelman DM, Bowie JU, Deber CM. The affinity of GXXXG motifs in transmembrane helix-helix interactions is modulated by long-range communication. J Biol Chem 2004; 279:16591-7.
48. Zhang J, Lazaridis T. Transmembrane helix association affinity can be modulated by flanking and noninterfacial residues. Biophys J 2009; 96:4418-27.
49. Bormann BJ, Engelman DM. Intramembrane helix-helix association in oligomerization and transmembrane signaling. Annu Rev Biophys Biomol Struct 1992; 21:223-42.
50. Jones DT. Do transmembrane protein superfolds exist? FEBS Lett 1998; 423:281-5.
51. Liu J, Rost B. Comparing function and structure between entire proteomes. Protein Sci 2001; 10:1970-9.
52. Ben-Shlomo I, Yu Hsu S, Rauch R, Kowalski HW, Hsueh AJ. Signaling receptome: a genomic and evolutionary perspective of plasma membrane receptors involved in signal transduction. Sci STKE 2003; RE9.
53. Orian-Rousseau V, Ponta H. Adhesion proteins meet receptors: a common theme? Adv Cancer Res 2008; 101:63-92.
54. Lemmon MA, Engelman DM. Specificity and promiscuity in membrane helix interactions. FEBS Lett 1994; 346:17-20.
55. MacKenzie KR, Engelman DM. Structure-based prediction of the stability of transmembrane helix-ìhelix interactions: The sequence dependence of glycophorin A dimerization. Proc Natl Acad Sci USA 1998; 95:3583-90.
56. Holt A, Killian JA. Orientation and dynamics of transmembrane peptides: the power of simple models. Eur Biophys J 2010; 39:609-21.
57. Killian JA, Nyholm TK. Peptides in lipid bilayers: the power of simple models. Curr Opin Struct Biol 2006; 16:473-9.
58. Cymer F, Schneider D. Lessons from viruses: controlling the function of transmembrane proteins by interfering transmembrane helices. Curr Med Chem 2008; 15:779-85.
59. Talbert-Slagle K, DiMaio D. The bovine papillomavirus E5 protein and the PDGF beta receptor: it takes two to tango. Virology 2009; 384:345-51.
60. Oates J, Hicks M, Dafforn TR, DiMaio D, Dixon AM. In vitro dimerization of the bovine papillomavirus E5 protein transmembrane domain. Biochemistry 2008; 47:8985-92.
61. Oates J, King G, Dixon AM. Strong oligomerization behavior of PDGFbeta receptor transmembrane domain and its regulation by the juxtamembrane regions. Biochim Biophys Acta 2010; 1798:605-15.
62. Cammett TJ, Jun SJ, Cohen EB, Barrera FN, Engelman DM, Dimaio D. Construction and genetic selection of small transmembrane proteins that activate the human erythropoietin receptor. Proc Natl Acad Sci USA 2010; 107:3447-52.
63. Robertson SC, Tynan JA, Donoghue DJ. RTK mutations and human syndromeswhen good receptors turn bad. Trends Genet 2000; 16:265-71.
64. Li E, Hristova K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 2006; 45:6241-51.
65. Partridge AW, Therien AG, Deber CM. Missense mutations in transmembrane domains of proteins: phenotypic propensity of polar residues for human disease. Proteins 2004; 54:648-56.
66. Mascle-Allemand C, Duquesne K, Lebrun R, Scheuring S, Sturgis JN. Antenna mixing in photosynthetic membranes from Phaeospirillum molischianum. Proc Natl Acad Sci 2010; 107:5357-62.
67. MacKenzie KR, Prestegard JH, Engelman DM. A transmembrane helix dimer: structure and implications. Science 1997; 276:131-3.
68. Bocharov EV, Mineev KS, Volynsky PE, Ermolyuk YS, Tkach EN, Sobol AG, et al. Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J Biol Chem 2008; 283:6950-6.
69. Bocharov EV, Mayzel ML, Volynsky PE, Goncharuk MV, Ermolyuk YS, Schulga AA, et al. Spatial structure and pH-dependent conformational diversity of dimeric transmembrane domain of the receptor tyrosine kinase EphA1. J Biol Chem 2008; 283:29385-95.
70. Bocharov EV, Mayzel ML, Volynsky PE, Mineev KS, Tkach EN, Ermolyuk YS, et al. Left-Handed Dimer of EphA2 Transmembrane Domain: Helix Packing Diversity among Receptor Tyrosine Kinases. Biophysical Journal 2010; 98:881-9.
71. Call ME, Schnell JR, Xu C, Lutz RA, Chou JJ, Wucherpfennig KW. The structure of the zetazeta transmembrane dimer reveals features essential for its assembly with the T cell receptor. Cell 2006; 127:355-68.
72. Sulistijo ES, Mackenzie KR. Structural basis for dimerization of the BNIP3 transmembrane domain. Biochemistry 2009; 48:5106-20.
73. Lau TL, Kim C, Ginsberg MH, Ulmer TS. The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling. EMBO J 2009; 28:1351-61.
74. Beevers AJ, Damianoglou A, Oates JE, Rodger A, Dixon AM. Sequence Dependent Oligomerization of the Neu Transmembrane Domain Suggests Inhibition of Conformational Switching' by Oncogenic Mutant. Biochemistry 2010; 49:2811-20.
75. Escher C, Cymer F, Schneider D. Two GxxxG-like motifs facilitate promiscuous interactions of the human ErbB transmembrane domains. J Mol Biol 2009; 389:10-6.
76. Gerber D, Sal-Man N, Shai Y. Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J Biol Chem 2004; 279:21177-82.
77. Yoda T, Sugita Y, Okamoto Y. Comparisons of force fields for proteins by generalized-ensemble simulations. Chem Phys Lett 2004; 386:460-7.
78. Lopera JA, Sturgis JN, Duneau JP. Ptuba: a tool for the visualization of helix surfaces in proteins. J Mol Graph Model 2005; 23:305-15.
79. Duneau JP, Vegh AP, Sturgis JN. A dimerization hierarchy in the transmembrane domains of the HER receptor family. Biochemistry 2007; 46:2010-9.
80. Stanley AM, Fleming KG. The transmembrane domains of ErbB receptors do not dimerize strongly in micelles. J Mol Biol 2005; 347:759-72.
81. Punta M, Forrest LR, Bigelow H, Kernytsky A, Liu J, Rost B. Membrane protein prediction methods. Methods 2007; 41:460-74.
82. Nam HJ, Jeon J, Kim S. Bioinformatic approaches for the structure and function of membrane proteins. BMB Rep 2009; 42:697-704.
83. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001; 305:567-80. (Pubitemid 33032862)
84. Rost B, Fariselli P, Casadio R. Topology prediction for helical transmembrane proteins at 86% accuracy. Protein Sci 1996; 5:1704-18. (Pubitemid 26257233)
85. Bernsel A, Viklund H, Falk J, Lindahl E, von Heijne G, Elofsson A. Prediction of membrane-protein topology from first principles. Proc Natl Acad Sci USA 2008; 105:7177-81.
86. Kall L, Krogh A, Sonnhammer EL. Advantages of combined transmembrane topology and signal peptide prediction - the Phobius web server. Nucleic Acids Res 2007; 35:429-32.
87. Stevens TJ, Arkin IT. Are membrane proteins "insideout" proteins? Proteins 1999; 36:135-43.
88. Adamian L, Liang J. Prediction of transmembrane helix orientation in polytopic membrane proteins. BMC Struct Biol 2006; 6:13.
89. Fuchs A, Martin-Galiano AJ, Kalman M, Fleishman S, Ben-Tal N, Frishman D. Co-evolving residues in membrane proteins. Bioinformatics 2007; 23:3312-9.
90. Lo A, Chiu YY, Rodland EA, Lyu PC, Sung TY, Hsu WL. Predicting helix-helix interactions from residue contacts in membrane proteins. Bioinformatics 2009; 25:996-1003.
91. Psachoulia E, Marshall DP, Sansom MS. Molecular Dynamics Simulations of the Dimerization of Transmembrane alpha-Helices. Acc Chem Res 2010; 43:388-96.
92. Samna Soumana O, Garnier N, Genest M. Molecular dynamics simulation approach for the prediction of transmembrane helix-helix heterodimers assembly. Eur Biophys J 2007; 36:1071-82.
93. Yin H, Slusky JS, Berger BW, Walters RS, Vilaire G, Litvinov RI, et al. Computational design of peptides that target transmembrane helices. Science 2007; 315:1817-22.
94. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009; 137:1293-307.
95. Lemmon MA. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009; 315:638-48.
96. Moriki T, Maruyama H, Maruyama IN. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 2001; 311:1011-26.
97. Tao RH, Maruyama IN. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci 2008; 121:3207-17.
98. Szabo A, Horvath G, Szollosi J, Nagy P. Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. Biophys J 2008; 95:2086-96.
99. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3:301-17.
100. George SR, Ng GY, Lee SP, Fan T, Varghese G, Wang C, et al. Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: novel strategy for functional inhibition of membrane proteins in vivo. J Pharmacol Exp Ther 2003; 307:481-9.
101. Lofts FJ, Hurst HC, Sternberg MJ, Gullick WJ. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 1993; 8:2813-20.
102. Manolios N, Collier S, Taylor J, Pollard J, Harrison LC, Bender V. T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Nat Med 1997; 3:84-8.
103. Nasarre C, Roth M, Jacob L, Roth L, Koncina E, Thien A, et al. Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. Oncogene 2010; 29:2381-92.
104. Quintana FJ, Gerber D, Bloch I, Cohen IR, Shai Y. A structurally altered D,L-amino acid TCRalpha transmembrane peptide interacts with the TCRalpha and inhibits T-cell activation in vitro and in an animal model. Biochemistry 2007; 46:2317-25.
105. Sal-Man N, Gerber D, Shai Y. Hetero-assembly between all-L- and all-D-amino acid transmembrane domains: forces involved and implication for inactivation of membrane proteins. J Mol Biol 2004; 344:855-64.
106. Gerber D, Shai Y. Chirality-independent protein-protein recognition between transmembrane domains in vivo. J Mol Biol 2002; 322:491-5.
107. Amon MA, Ali M, Bender V, Chan YN, Toth I, Manolios N. Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. Biochim Biophys Acta 2006; 1763:879-88.
108. Finger C, Escher C, Schneider D. The Single Transmembrane Domains of Human Receptor Tyrosine Kinases Encode Self-Interactions. Sci Signal 2009; 2:ra56.
109. Mendrola JM, Berger MB, King MC, Lemmon MA. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem 2002; 277:4704-12.
110. He L, Hristova K. Pathogenic activation of receptor tyrosine kinases in mammalian membranes. J Mol Biol 2008; 384:1130-42.
111. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45:649-57.
112. Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 1997; 14:687-96.
113. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Cremel G, et al. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 2004; 15:3464-74.
114. Webster MK, Donoghue DJ. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO Journal 1996; 15:520-7.
115. Li Y, Mangasarian K, Mansukhani A, Basilico C. Activation of FGF receptors by mutations in the transmembrane domain. Oncogene 1997; 14:1397-406. (Pubitemid 27182429)
116. Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20:3553-62.
117. Iwamoto T, You M, Li E, Spangler J, Tomich JM, Hristova K. Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications. Biochim Biophys Acta 2005; 1668:240-7.
118. Li E, You M, Hristova K. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J Mol Biol 2006; 356:600-12.
119. Merzlyakov M, Chen L, Hristova K. Studies of receptor tyrosine kinase transmembrane domain interactions: the EmEx-FRET method. J Membr Biol 2007; 215:93-103.
120. You M, Spangler J, Li E, Han X, Ghosh P, Hristova K. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers. Biochemistry 2007; 46:11039-46.
121. Peng WC, Lin X, Torres J. The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues. Protein Sci 2009; 18:450-9.
122. Dosch DD, Ballmer-Hofer K. Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers. Faseb Journal 2010; 24:32-8.
123. Talbert-Slagle K, Marlatt S, Barrera FN, Khurana E, Oates J, Gerstein M, et al. Artificial transmembrane oncoproteins smaller than the bovine papillomavirus E5 protein redefine sequence requirements for activation of the platelet-derived growth factor beta receptor. J Virol 2009; 83:9773-85.
124. Kjaer S, Kurokawa K, Perrinjaquet M, Abrescia C, Ibanez CF. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. Oncogene 2006; 25:7086-95.
125. Constantinescu SN, Liu X, Beyer W, Fallon A, Shekar S, Henis YI, et al. Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain. EMBO J 1999; 18:3334-47.
126. Kubatzky KF, Ruan W, Gurezka R, Cohen J, Ketteler R, Watowich SS, et al. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol 2001; 11:110-5.
127. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 2003; 12:1239-50.
128. Ebie AZ, Fleming KG. Dimerization of the erythropoietin receptor transmembrane domain in micelles. J Mol Biol 2007; 366:517-24.
129. Becker V, Sengupta D, Ketteler R, Ullmann GM, Smith JC, Klingmuller U. Packing density of the erythropoietin receptor transmembrane domain correlates with amplification of biological responses. Biochemistry 2008; 47:11771-82.
130. Gadd SL, Clevenger CV. Ligand-Independent Dimerization of the Human Prolactin Receptor Isoforms: Functional Implications. Mol Endocrinol 2006; 20:2734-46.
131. Artemenko EO, Egorova NS, Arseniev AS, Feofanov AV. Transmembrane domain of EphA1 receptor forms dimers in membrane-like environment. Biochim Biophys Acta 2008; 1778:2361-7.
132. Cheatham B, Shoelson SE, Yamada K, Goncalves E, Kahn CR. Substitution of the erbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin and insulin-receptor substrate 1. Proc Natl Acad Sci USA 1993; 90:7336-40.
133. Chan JLK, Lai M, Wang LH. Effect of dimerization on signal transduction and biological function of oncogenic Ros, insulin and insulin-like growth factor I receptors. Journal of Biological Chemistry 1997; 272:146-53.
134. Gardin A, Auzan C, Clauser E, Malherbe T, Aunis D, Cremel G, et al. Substitution of the insulin receptor transmembrane domain with that of glycophorin A inhibits insulin action. Faseb J 1999; 13:1347-57.
135. Chin CN, Sachs JN, Engelman DM. Transmembrane homodimerization of receptor-like protein tyrosine phosphatases. FEBS Lett 2005; 579:3855-8.
136. Roth L, Nasarre C, Dirrig-Grosch S, Aunis D, Cremel G, Hubert P, et al. Transmembrane domain interactions control biological functions of neuropilin-1. Mol Biol Cell 2008; 19:646-54.
137. Blumberg RS, Alarcon B, Sancho J, McDermott FV, Lopez P, Breitmeyer J, et al. Assembly and function of the T cell antigen receptor. Requirement of either the lysine or arginine residues in the transmembrane region of the alpha chain. J Biol Chem 1990; 265:14036-43.
138. Rutledge T, Cosson P, Manolios N, Bonifacino JS, Klausner RD. Transmembrane helical interactions: zeta chain dimerization and functional association with the T cell antigen receptor. EMBO J 1992; 11:3245-54.
139. Fuller-Espie S, Hoffman Towler P, Wiest DL, Tietjen I, Spain LM. Transmembrane polar residues of TCRbeta chain are required for signal transduction. Int Immunol 1998; 10:923-33.
140. Cosson P, Bonifacino JS. Role of transmembrane domain interactions in the assembly of class II MHC molecules. Science 1992; 258:659-62.
141. Li R, Babu CR, Lear JD, Wand AJ, Bennett JS, DeGrado WF. Oligomerization of the integrin alphaIIbbeta3: roles of the transmembrane and cytoplasmic domains. Proc Natl Acad Sci USA 2001; 98:12462-7.
142. Schneider D, Engelman DM. Involvement of transmembrane domain interactions in signal transduction by alpha/beta integrins. J Biol Chem 2004; 279:9840-6.
143. Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol 2005; 21:381-410.
144. Lin X, Tan SM, Law SK, Torres J. Two types of transmembrane homomeric interactions in the integrin receptor family are evolutionarily conserved. Proteins 2006; 63:16-23.
145. Litvinov RI, Vilaire G, Li W, DeGrado WF, Weisel JW, Bennett JS. Activation of individual alphaIIbbeta3 integrin molecules by disruption of transmembrane domain interactions in the absence of clustering. Biochemistry 2006; 45:4957-64.
146. Yin H, Litvinov RI, Vilaire G, Zhu H, Li W, Caputo GA, et al. Activation of platelet alphaIIbbeta3 by an exogenous peptide corresponding to the transmembrane domain of alphaIIb. J Biol Chem 2006; 281:36732-41.
147. Dews IC, Mackenzie KR. Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions. Proc Natl Acad Sci USA 2007; 104:20782-7.
148. Choi S, Lee E, Kwon S, Park H, Yi JY, Kim S, et al. Transmembrane domain-induced oligomerization is crucial for the functions of syndecan-2 and syndecan-4. J Biol Chem 2005; 280:42573-9.
149. Plotkowski ML, Kim S, Phillips ML, Partridge AW, Deber CM, Bowie JU. Transmembrane domain of myelin protein zero can form dimers: possible implications for myelin construction. Biochemistry 2007; 46:12164-73.
150. Huber O, Kemler R, Langosch D. Mutations affecting transmembrane segment interactions impair adhesiveness of E-cadherin. J Cell Sci 1999; 112:4415-23. (Pubitemid 30122033)
151. Yonekura S, Ting CY, Neves G, Hung K, Hsu SN, Chiba A, et al. The variable transmembrane domain of Drosophila N-cadherin regulates adhesive activity. Mol Cell Biol 2006; 26:6598-608.
152. Bowen ME, Engelman DM, Brunger AT. Mutational analysis of synaptobrevin transmembrane domain oligomerization. Biochemistry 2002; 41:15861-6.
153. Laage R, Langosch D. Dimerization of the synaptic vesicle protein synaptobrevin (vesicle-associated membrane protein) II depends on specific residues within the transmembrane segment. European Journal of Biochemistry 1997; 249:540-6. (Pubitemid 27455798)
154. Lemmon MA, Flanagan JM, Hunt JF, Adair BD, Bormann BJ, Dempsey CE, et al. Glycophorin A dimerization is driven by specific interactions between transmembrane alpha-helices. J Biol Chem 1992; 267:7683-9.
155. MacKenzie KR, Engelman DM. Structure-based prediction of the stability of transmembrane helix-helix interactions: the sequence dependence of glycophorin A dimerization. Proc Natl Acad Sci USA 1998; 95:3583-90.
156. Fisher LE, Engelman DM, Sturgis JN. Detergents modulate dimerization, but not helicity, of the glycophorin A transmembrane domain. J Mol Biol 1999; 293:639-51.
157. Russ WP, Engelman DM. TOXCAT: a measure of transmembrane helix association in a biological membrane. Proc Natl Acad Sci USA 1999; 96:863-8.
158. Sulistijo ES, MacKenzie KR. Sequence dependence of BNIP3 transmembrane domain dimerization implicates side-chain hydrogen bonding and a tandem GxxxG motif in specific helix-helix interactions. J Mol Biol 2006; 364:974-90.
159. Marchesi VT. An alternative interpretation of the amyloid Abeta hypothesis with regard to the pathogenesis of Alzheimer's disease. Proc Natl Acad Sci USA 2005; 102:9093-8.
160. Kienlen-Campard P, Tasiaux B, Van Hees J, Li M, Huysseune S, Sato T, et al. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem 2008; 283:7733-44.
161. Sato T, Tang TC, Reubins G, Fei JZ, Fujimoto T, Kienlen-Campard P, et al. A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc Natl Acad Sci USA 2009; 106:1421-6.
162. Munter LM, Voigt P, Harmeier A, Kaden D, Gottschalk KE, Weise C, et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J 2007; 26:1702-12.
163. Bargmann CI, Weinberg RA. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA 1988; 85:5394-8.
164. Siddig A, Mohamed AO, Kamal H, Awad S, Hassan AH, Zilahi E, et al. HER-2/neu Ile655Val polymorphism and the risk of breast cancer. Ann N Y Acad Sci 2008; 1138:84-94.
165. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 2005; 76:361-7.
166. Przylepa KA, Paznekas W, Zhang M, Golabi M, Bias W, Bamshad MJ, et al. Fibroblast growth factor receptor 2 mutations in Beare-Stevenson Cutis gyrata syndrome. Nat Genet 1996; 13:492-4.
167. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with Acanthosis nigricans. Nat Genet 1995; 11:462-4.
168. Bonaventure J, Rousseau F, Legeai-Mallet L, Le Merrer M, Munnich A, Maroteaux P. Common mutations in the gene encoding fibroblast growth factor receptor 3 account for achondroplasia, hypochondroplasia and thanatophoric dysplasia. Acta Paediatr Suppl 1996; 417:33-8.
169. Webster MK, Donoghue DJ. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997; 13:178-82.
170. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62:840-7.
171. Bucheton B, Argiro L, Chevillard C, Marquet S, Kheir MM, Mergani A, et al. Identification of a novel G245R polymorphism in the IL-2 receptor beta membrane proximal domain associated with human visceral leishmaniasis. Genes Immun 2007; 8:79-83.
172. Hayasaka K, Himoro M, Sawaishi Y, Nanao K, Takahashi T, Takada G, et al. De novo mutation of the myelin P0 gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III). Nat Genet 1993; 5:266-8.
173. Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K, et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 2002; 51:190-201.
174. Eggers SD, Keswani SC, Melli G, Cornblath DR. Clinical and genetic description of a family with Charcot-Marie-Tooth disease type 1B from a transmembrane MPZ mutation. Muscle Nerve 2004; 29:867-9.
175. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37:829-34.
176. Daley DO, Rapp M, Granseth E, Melen K, Drew D, von Heijne G. Global topology analysis of the Escherichia coli inner membrane proteome. Science 2005; 308:1321-3.
177. Almen MS, Nordstrom KJ, Fredriksson R, Schioth HB. Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin. BMC Biol 2009; 7:50.
178. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14:33-8.